Spots Global Cancer Trial Database for endocrine gland neoplasms
Every month we try and update this database with for endocrine gland neoplasms cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca | NCT01555489 | Stage IV Pancre... | Ascorbic Acid | 18 Years - | Thomas Jefferson University | |
| Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy | NCT05022667 | Thyroid Neoplas... Thyroid Disease... Hypoparathyroid... Endocrine Syste... Endocrine Gland... Neoplasms by Si... Neoplasms Head and Neck N... Parathyroid Dis... | PTeye | 18 Years - | University of Michigan | |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | NCT03093116 | Locally Advance... Metastatic Soli... | Oral repotrecti... | 12 Years - | Turning Point Therapeutics, Inc. | |
| A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma | NCT02993731 | Carcinoma, Panc... | Napabucasin Nab-paclitaxel Gemcitabine | 18 Years - | Sumitomo Pharma America, Inc. | |
| A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) | NCT03157128 | Non-Small Cell ... Medullary Thyro... Colon Cancer Any Solid Tumor | LOXO-292 | 12 Years - | Eli Lilly and Company | |
| A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer | NCT03535727 | Adenocarcinoma Pancreatic Neop... Neoplasm, Gland... Neoplasms Neoplasms Pancr... Digestive Syste... Endocrine Gland... Digestive Syste... Pancreatic Dise... Endocrine Syste... | Nab-paclitaxel Gemcitabine Capecitabine Cisplatin Irinotecan Nab-paclitaxel Gemcitabine Capecitabine Cisplatin Irinotecan | 18 Years - 76 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Prospective Validation and Comparison of Different Ultrasound Methods for Discrimination Between Benign and Malignant Ovarian/Tubal Masses Prior to Surgery | NCT02847832 | Patients With A... | Standardized tr... | - | KU Leuven | |
| Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma | NCT03717298 | Adenocarcinoma ... Pancreatic Canc... Advanced Cancer Digestive Syste... Pancreatic Neop... Endocrine Gland... Digestive Syste... Endocrine Syste... Pancreatic Dise... | Ocoxin-Viusid® | 18 Years - | Catalysis SL | |
| Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca | NCT01555489 | Stage IV Pancre... | Ascorbic Acid | 18 Years - | Thomas Jefferson University | |
| Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy | NCT05152927 | Parathyroid Dis... Parathyroid Dys... Parathyroid Neo... Parathyroid Ade... Hypercalcemia Neoplasms, Glan... Endocrine Gland... Adenoma Hyperparathyroi... Hyperparathyroi... | Parathyroid Eye... | 18 Years - | University of California, San Francisco | |
| Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | NCT02909452 | Neoplasms Neoplasms, Glan... Neoplasms by Hi... Bronchial Neopl... Lung Neoplasms Respiratory Tra... Thoracic Neopla... Digestive Syste... Endocrine Gland... Carcinoma, Non-... Lung Diseases Breast Diseases Renal Neoplasm Solid Tumors | Entinostat Pembrolizumab | 18 Years - | Syndax Pharmaceuticals | |
| A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8) | NCT00749502 | Solid Tumors Chronic Lymphoc... T-cell-prolymph... | MK-4827 | 18 Years - | Tesaro, Inc. | |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | NCT03093116 | Locally Advance... Metastatic Soli... | Oral repotrecti... | 12 Years - | Turning Point Therapeutics, Inc. | |
| Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma | NCT03717298 | Adenocarcinoma ... Pancreatic Canc... Advanced Cancer Digestive Syste... Pancreatic Neop... Endocrine Gland... Digestive Syste... Endocrine Syste... Pancreatic Dise... | Ocoxin-Viusid® | 18 Years - | Catalysis SL | |
| A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors | NCT03899792 | Medullary Thyro... Infantile Myofi... Infantile Fibro... Papillary Thyro... Soft Tissue Sar... | LOXO-292 | 6 Months - 21 Years | Eli Lilly and Company | |
| Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors | NCT02897778 | Neoplasms Neoplasms, Glan... Neoplasms by Hi... Bronchial Neopl... Lung Neoplasms Respiratory Tra... Thoracic Neopla... Digestive Syste... Endocrine Gland... Carcinoma, Non-... Lung Diseases Breast Neoplasm... Breast Diseases Renal Neoplasm Solid Tumors | Entinostat Placebo | 18 Years - | Syndax Pharmaceuticals | |
| A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors | NCT03899792 | Medullary Thyro... Infantile Myofi... Infantile Fibro... Papillary Thyro... Soft Tissue Sar... | LOXO-292 | 6 Months - 21 Years | Eli Lilly and Company | |
| A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer | NCT02231723 | Metastatic Panc... | BBI608 Nab-paclitaxel Gemcitabine Oxaliplatin Leucovorin Irinotecan Fluorouracil MM-398 | 18 Years - | Sumitomo Pharma America, Inc. | |
| Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | NCT01964430 | Pancreatic Neop... Digestive Syste... Neoplasms by Si... Neoplasms Endocrine Gland... Pancreatic Dise... Digestive Syste... Endocrine Syste... Gemcitabine Antimetabolites... | nab-Paclitaxel Gemcitabine | 18 Years - | Celgene | |
| Establishment of a Tumor Bank for Blood Samples | NCT01763125 | Ovarian Neoplas... Breast Neoplasm... Colorectal Neop... Neoplasms of th... Lung Neoplasms Endocrine Gland... | Blood collectio... | 18 Years - | Medical University of Vienna | |
| Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors | NCT01215578 | Neuroendocrine ... Pancreatic Neop... Advanced Diseas... Sunitinib | Sutent | 18 Years - | Assistance Publique - Hôpitaux de Paris |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
